CN105764529A - 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒 - Google Patents

用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒 Download PDF

Info

Publication number
CN105764529A
CN105764529A CN201480051858.9A CN201480051858A CN105764529A CN 105764529 A CN105764529 A CN 105764529A CN 201480051858 A CN201480051858 A CN 201480051858A CN 105764529 A CN105764529 A CN 105764529A
Authority
CN
China
Prior art keywords
carrier molecule
disease
receptor substrate
cell
dextran backbone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480051858.9A
Other languages
English (en)
Chinese (zh)
Inventor
F·科普
M·布卢
W·梅茨
L·施勒辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Candler Health 414 LLC
Ohio State Innovation Foundation
Original Assignee
Navidea Biopharmaceuticals Inc
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navidea Biopharmaceuticals Inc, Ohio State Innovation Foundation filed Critical Navidea Biopharmaceuticals Inc
Priority to CN202111299877.1A priority Critical patent/CN114377143A/zh
Publication of CN105764529A publication Critical patent/CN105764529A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
CN201480051858.9A 2013-07-22 2014-07-22 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒 Pending CN105764529A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111299877.1A CN114377143A (zh) 2013-07-22 2014-07-22 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361857232P 2013-07-22 2013-07-22
US61/857,232 2013-07-22
US201361879649P 2013-09-18 2013-09-18
US61/879,649 2013-09-18
PCT/US2014/047708 WO2015013341A1 (en) 2013-07-22 2014-07-22 Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111299877.1A Division CN114377143A (zh) 2013-07-22 2014-07-22 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒

Publications (1)

Publication Number Publication Date
CN105764529A true CN105764529A (zh) 2016-07-13

Family

ID=51352773

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480051858.9A Pending CN105764529A (zh) 2013-07-22 2014-07-22 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
CN202111299877.1A Pending CN114377143A (zh) 2013-07-22 2014-07-22 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111299877.1A Pending CN114377143A (zh) 2013-07-22 2014-07-22 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒

Country Status (11)

Country Link
US (2) US20150023876A1 (enExample)
EP (1) EP3024493A1 (enExample)
JP (1) JP6607854B2 (enExample)
KR (2) KR20210095972A (enExample)
CN (2) CN105764529A (enExample)
AU (3) AU2014293198A1 (enExample)
CA (1) CA2918782C (enExample)
HK (1) HK1225623A1 (enExample)
IL (1) IL243645B (enExample)
WO (1) WO2015013341A1 (enExample)
ZA (1) ZA201600453B (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110139655A (zh) * 2016-10-07 2019-08-16 纳维迪亚生物制药有限公司 诊断和治疗病毒性感染的化合物和方法
CN110997014A (zh) * 2017-05-19 2020-04-10 纳维迪亚生物制药有限公司 Cd206+巨噬细胞-特异性分子成像探针组合物和方法以及人类动脉壁巨噬细胞浸润的非侵入性量化
CN111447955A (zh) * 2017-07-21 2020-07-24 纳维迪亚生物制药有限公司 99mTc-替马诺塞和相关的分子构建体用于鉴定和诊断恶性肿瘤和用于监测治疗性抗肿瘤干预的用途
CN113899909A (zh) * 2021-09-30 2022-01-07 上海交通大学医学院附属瑞金医院 可溶性cd206在制备抗中性粒细胞胞浆抗体相关性血管炎诊断试剂盒中的应用
CN113950374A (zh) * 2019-03-01 2022-01-18 维迪亚控股有限公司 分析装置中试剂的布置
CN114025666A (zh) * 2019-01-25 2022-02-08 纳维迪亚生物制药有限公司 用于评估巨噬细胞介导的病理学的组合物和方法
CN114555131A (zh) * 2019-08-19 2022-05-27 纳维迪亚生物制药有限公司 用于消融m2巨噬细胞和髓源性抑制细胞的组合物和相关方法
CN115151264A (zh) * 2019-09-30 2022-10-04 纳维迪亚生物制药有限公司 用于阻断甘露糖基化葡聚糖和其它cd206配体脱靶定位的组合物和相关方法
CN119592679A (zh) * 2024-11-25 2025-03-11 中日友好医院(中日友好临床医学研究所) 一种用于评估皮肌炎/抗合成酶综合征相关间质性肺疾病严重程度及预后的新型标记物及其应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
JP6722663B2 (ja) * 2014-07-17 2020-07-15 オハイオ ステート イノベーション ファウンデーション マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法
JP2018528235A (ja) * 2015-09-25 2018-09-27 セリーン・エルエルシー Ｓｎ−１１７ｍ標識マンノース結合デキストランアミン
MX2019003897A (es) * 2016-10-04 2019-11-18 Cardinal Health 414 Llc Composiciones y metodos para el diagnostico y el tratamiento de trastornos relacionados con macrofagos que utilizan el transportador macromolecular a base de carbohidratos.
MX2019004033A (es) * 2016-10-07 2019-12-05 Navidea Biopharmaceuticals Inc Compuestos y composiciones para el tratamiento de la leishmaniasis y metodos de diagnostico y tratamiento que utilizan los mismos.
US11363709B2 (en) 2017-02-24 2022-06-14 BWXT Isotope Technology Group, Inc. Irradiation targets for the production of radioisotopes
US11286172B2 (en) 2017-02-24 2022-03-29 BWXT Isotope Technology Group, Inc. Metal-molybdate and method for making the same
MX2021011703A (es) * 2019-03-27 2022-01-06 Navidea Biopharmaceuticals Inc Composiciones y métodos para alterar el fenotipo de macrófagos.
GB201915222D0 (en) * 2019-10-21 2019-12-04 Univ Court Univ Of Glasgow Diagnostic and prognostic biomarkers of disease remission in rheumatoid arthritis
JP2023533405A (ja) * 2020-07-08 2023-08-03 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド 均一に定められた分子量のマンノシル化デキストランおよびその誘導体の合成
WO2022157373A1 (en) * 2021-01-25 2022-07-28 Vrije Universiteit Brussel Compositions and kits for in vivo imaging of cardiac sarcoidosis
EP4472643A1 (en) 2022-02-04 2024-12-11 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
WO2023183922A2 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive self-blocking with unlabeled manocept imaging agents
EP4525882A1 (en) 2022-05-20 2025-03-26 Navidea Biopharmaceuticals, Inc. Cd206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker
US12404349B2 (en) 2022-10-03 2025-09-02 Navidea Biopharmaceuticals, Inc. Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers
WO2024178142A1 (en) * 2023-02-22 2024-08-29 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6409990B1 (en) * 1999-05-14 2002-06-25 The Regents Of The University Of California Macromolecular carrier for drug and diagnostic agent delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004085929A (ja) * 2002-08-27 2004-03-18 Fuji Photo Optical Co Ltd 光学素子
US20090311182A1 (en) * 2004-03-31 2009-12-17 Dong Wang Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
SG166016A1 (en) * 2009-04-16 2010-11-29 Fan Wang Yiang Financial education planner and method of using thereof
US9101674B2 (en) * 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US20130330274A1 (en) * 2012-05-22 2013-12-12 University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group Compositions and methods for detecting and treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6409990B1 (en) * 1999-05-14 2002-06-25 The Regents Of The University Of California Macromolecular carrier for drug and diagnostic agent delivery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
左大明，陈政良: "巨噬细胞甘露糖受体的结构与功能", 《免疫学杂志》 *
王晓蕾等: "巨噬细胞摄取结核分支杆菌相关的受体", 《中华结核和呼吸杂志》 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12005122B2 (en) 2016-10-07 2024-06-11 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
CN110139655A (zh) * 2016-10-07 2019-08-16 纳维迪亚生物制药有限公司 诊断和治疗病毒性感染的化合物和方法
CN110997014A (zh) * 2017-05-19 2020-04-10 纳维迪亚生物制药有限公司 Cd206+巨噬细胞-特异性分子成像探针组合物和方法以及人类动脉壁巨噬细胞浸润的非侵入性量化
CN111447955A (zh) * 2017-07-21 2020-07-24 纳维迪亚生物制药有限公司 99mTc-替马诺塞和相关的分子构建体用于鉴定和诊断恶性肿瘤和用于监测治疗性抗肿瘤干预的用途
CN114025666A (zh) * 2019-01-25 2022-02-08 纳维迪亚生物制药有限公司 用于评估巨噬细胞介导的病理学的组合物和方法
CN113950374B (zh) * 2019-03-01 2023-07-28 维迪亚控股有限公司 分析装置中试剂的布置
CN113950374A (zh) * 2019-03-01 2022-01-18 维迪亚控股有限公司 分析装置中试剂的布置
CN114555131A (zh) * 2019-08-19 2022-05-27 纳维迪亚生物制药有限公司 用于消融m2巨噬细胞和髓源性抑制细胞的组合物和相关方法
CN115151264B (zh) * 2019-09-30 2024-03-12 纳维迪亚生物制药有限公司 用于阻断甘露糖基化葡聚糖和其它cd206配体脱靶定位的组合物和相关方法
CN115151264A (zh) * 2019-09-30 2022-10-04 纳维迪亚生物制药有限公司 用于阻断甘露糖基化葡聚糖和其它cd206配体脱靶定位的组合物和相关方法
CN113899909A (zh) * 2021-09-30 2022-01-07 上海交通大学医学院附属瑞金医院 可溶性cd206在制备抗中性粒细胞胞浆抗体相关性血管炎诊断试剂盒中的应用
CN119592679A (zh) * 2024-11-25 2025-03-11 中日友好医院(中日友好临床医学研究所) 一种用于评估皮肌炎/抗合成酶综合征相关间质性肺疾病严重程度及预后的新型标记物及其应用
CN119592679B (zh) * 2024-11-25 2025-06-24 中日友好医院(中日友好临床医学研究所) 一种用于评估皮肌炎/抗合成酶综合征相关间质性肺疾病严重程度及预后的新型标记物及其应用

Also Published As

Publication number Publication date
AU2020200293A1 (en) 2020-02-06
AU2022205225A1 (en) 2022-08-04
IL243645B (en) 2019-12-31
WO2015013341A1 (en) 2015-01-29
JP6607854B2 (ja) 2019-11-20
KR20160055791A (ko) 2016-05-18
US20220016272A1 (en) 2022-01-20
AU2020200293B2 (en) 2022-04-21
KR102284389B1 (ko) 2021-08-03
EP3024493A1 (en) 2016-06-01
CA2918782A1 (en) 2015-01-29
ZA201600453B (en) 2019-09-25
IL243645A0 (en) 2016-02-29
JP2016527252A (ja) 2016-09-08
CN114377143A (zh) 2022-04-22
AU2014293198A1 (en) 2016-02-04
HK1225623A1 (zh) 2017-09-15
US20150023876A1 (en) 2015-01-22
KR20210095972A (ko) 2021-08-03
CA2918782C (en) 2024-03-12

Similar Documents

Publication Publication Date Title
AU2020200293B2 (en) Compositions, methods and kits for diagnosing and treating CD206 expressing cell-related disorders
US12097264B2 (en) Methods and compositions for theranostic nanoparticles
ES2787099T3 (es) Fucoidanos como ligandos para el diagnóstico de patologías degenerativas
Lesniak et al. Evaluation of PSMA-targeted PAMAM dendrimer nanoparticles in a murine model of prostate cancer
Kang et al. 64Cu-Labeled tetraiodothyroacetic acid-conjugated liposomes for PET imaging of tumor angiogenesis
Chen et al. Multifunctional gold nanocomposites designed for targeted CT/MR/optical trimodal imaging of human non-small cell lung cancer cells
JP2010513476A (ja) 造影剤
US20210338848A1 (en) Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier
HK40073647A (en) Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
US20220280659A1 (en) Targeted Nanoparticles of Well-Defined and Reproducible Sizes
JP6395880B2 (ja) 変性病変の診断のためのリガンドとしてのフコイダン
JP6099055B2 (ja) 変性病変の診断のためのリガンドとしてのフコイダン
Müller et al. Folate Receptor-Targeted Radionuclide Imaging Agents
Jia et al. speCt/NIRF Dual Modality Imaging for Detection of Intraperitoneal Colon tumor with an Avidin/Biotin pretargeting system

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1225623

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20171227

Address after: ohio

Applicant after: Candler health 414 limited liability company

Applicant after: OHIO STATE INNOVATION FOUNDATION

Address before: American Ohio

Applicant before: NAVIDEA BIOPHARMACEUTICALS INC

Applicant before: OHIO STATE INNOVATION FOUNDATION

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20160713

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1225623

Country of ref document: HK